Veeva Systems Inc. (VEEV) Launches eSource to Streamline Clinical Trial Data

Veeva Systems Inc. (NYSE:VEEV) is among the 20 Best Investments in 2026.

The fifth stock on our list of best investment stocks is Veeva Systems Inc. (NYSE:VEEV).

TheFly reported on February 20 that UBS reduced its price target on VEEV to $200 from $280 while maintaining a Neutral rating on the stock.

Veeva Systems Inc. (NYSE:VEEV) made a significant announcement on January 29 when it unveiled Veeva eSource, a new application within its SiteVault platform designed to improve data accuracy and reduce manual operations in clinical trials.

The solution enables direct digital capture of trial information at research sites, removing reliance on paper records. It integrates with electronic health records to transfer relevant patient data and connects with electronic data capture systems to automate data flow to sponsors. By minimizing duplicate entry and eliminating traditional source data verification processes, the application is designed to lower administrative burden, decrease errors, and accelerate study execution. Veeva eSource also features open API connectivity and is expected to become available to early adopters in the second half of 2026.

Moreover, on February 11, VEEV announced it will release its fiscal 2026 fourth quarter and full-year financial results on March 4, 2026.

Veeva Systems Inc. (NYSE:VEEV) provides cloud-based software solutions for the life sciences industry, supporting drug development, regulatory compliance, and commercial operations.

While we acknowledge the potential of VEEV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the